Kamada/$KMDA
1D1W1MYTD1Y5YMAX
Capital at risk
About Kamada
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
- Ticker
- $KMDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 462
- Headquarters
- Rehovot, Israel
- Website
- www.kamada.com
Kamada Metrics
BasicAdvanced
$476M
21.76
$0.38
0.13
$0.25
3.02%
Price and volume
Market cap
$476M
Beta
0.13
52-week high
$9.35
52-week low
$6.50
Average daily volume
153K
Dividend rate
$0.25
Financial strength
Current ratio
4.06
Quick ratio
2.293
Long term debt to equity
3.53
Total debt to equity
4.378
Dividend payout ratio (TTM)
64.81%
Interest coverage (TTM)
26.79%
Profitability
EBITDA (TTM)
41.494
Gross margin (TTM)
40.82%
Net profit margin (TTM)
11.60%
Operating margin (TTM)
14.51%
Effective tax rate (TTM)
16.60%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
4.63%
Return on equity (TTM)
8.40%
Valuation
Price to earnings (TTM)
21.762
Price to revenue (TTM)
2.524
Price to book
5.34
Price to tangible book (TTM)
9.91
Price to free cash flow (TTM)
18.402
Free cash flow yield (TTM)
5.43%
Free cash flow per share (TTM)
0.45
Dividend yield (TTM)
3.02%
Forward dividend yield
3.02%
Growth
Revenue change (TTM)
13.17%
Earnings per share change (TTM)
19.00%
3-year revenue growth (CAGR)
9.58%
10-year revenue growth (CAGR)
9.76%
3-year earnings per share growth (CAGR)
71.40%
10-year earnings per share growth (CAGR)
6.11%
What the Analysts think about Kamada
Analyst ratings (Buy, Hold, Sell) for Kamada stock.
Analyst projections of the future price of Kamada stock.
Bulls say / Bears say
Kamada delivered record-high first half revenues of $100.2 million, a 13% increase year-over-year driven by strong sales of KEDRAB, VARIZIG and HEPAGAM. (Nasdaq)
Record-high adjusted EBITDA of $25.7 million in the first half of 2026, representing a 26% margin and up 14% year-over-year, demonstrates robust profitability and operational efficiency. (Nasdaq)
Strong operating cash flow of $17.8 million during H1 2026 (versus $7.5 million in H1 2025) coupled with a strategic three-year, $50 million plasma supply agreement enhances revenue visibility and cash-flow generation. (Nasdaq)
Gross margins for the first six months of 2026 contracted to 42% from 45% in the same period last year, indicating rising cost pressures on Kamada’s core plasma-derived product lines. (Nasdaq)
Cash and cash equivalents and short-term investments declined to $70.1 million as of June 30, 2026, down from $75.5 million at December 31, 2025 after a $14.4 million dividend payment, potentially constraining financial flexibility for R&D and M&A. (Nasdaq)
The FDA’s proposal to ease approval requirements for biosimilar drugs could lower barriers to entry for competitors targeting Kamada’s plasma-derived therapeutics, threatening product exclusivity and pricing power. (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Kamada Financial Performance
Revenues and expenses
Kamada Earnings Performance
Company profitability
Upcoming events
Funds containing Kamada
AllUSDGBP
Fund name | Fund size | $KMDA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.